In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, Steven M. Silverstein, MD, discusses the results of a phase 3 study of Dextenza for the treatment of allergic conjunctivitis.
The study found the dexamethasone ophthalmic insert 0.4 mg from Ocular Therapeutix was effective at treating the signs and symptoms of seasonal and perennial ocular allergies.
Uncategorized